Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
068270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068270008
- LEI:
- Country:
- South Korea
- Address:
- 인천광역시 연수구 아카데미로 23, 인천광역시
- Website:
- https://www.celltrion.com/
- Sector:
- Manufacturing
Description
Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-30 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 7.5 KB | ||
| 2022-03-29 00:00 |
자기주식취득결과보고서
|
Korean | 26.0 KB | ||
| 2022-03-25 00:00 |
정기주주총회결과
|
Korean | 36.4 KB | ||
| 2022-03-25 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 14.2 KB | ||
| 2022-03-25 00:00 |
주식매수선택권부여에관한신고
|
Korean | 46.1 KB | ||
| 2022-03-17 00:00 |
[기재정정]사업보고서 (2021.12)
|
Korean | 2.4 MB | ||
| 2022-03-11 00:00 |
기타경영사항(자율공시)
|
Korean | 7.9 KB | ||
| 2022-03-08 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 512.0 KB | ||
| 2022-03-08 00:00 |
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경
|
Korean | 26.5 KB | ||
| 2022-03-08 00:00 |
감사보고서제출
|
Korean | 18.7 KB | ||
| 2022-03-08 00:00 |
주주총회소집공고
|
Korean | 421.3 KB | ||
| 2022-03-08 00:00 |
의결권대리행사권유참고서류
|
Korean | 409.8 KB | ||
| 2022-03-08 00:00 |
사업보고서 (2021.12)
|
Korean | 571.5 KB | ||
| 2022-03-08 00:00 |
주주총회집중일개최사유신고
|
Korean | 4.9 KB | ||
| 2022-02-25 00:00 |
투자판단관련주요경영사항(CT-P63+CT-P66(코로나19 흡입형 치료제) 유럽 임상 3상 시험계획 신청)
|
Korean | 11.0 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celltrion, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
